Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Cholesterol/Lipid Disorders
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Cholesterol/Lipid Disorders
    Atorvastatin Improves Dyslipidaemia in Patients With Coronary Heart Disease, May Be Renoprotective: Presented at Renal Week 2009 - (DGDispatch)
    Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents - (JAMA)
    TopAbstracts in Cholesterol/Lipid Disorders 10/29/2009 - (DGNews)
    Addition of Ezetimibe Helps More Elderly Achieve LDL Cholesterol Goal Than Uptitration of Atorvastatin: Presented at CCC - (DGDispatch)
    New Canadian Cholesterol-Lowering Guidelines Target Immediate-Risk Group: Presented at CCC - (DGDispatch)

    News archive

     Recent webcasts/CME - Cholesterol/Lipid Disorders
    • Optimizing Management of Dyslipidemia: Risk Assessment, Treatment Targets, and Adherence
    • Assessing Cardiovascular Risk
    • Setting Treatment Goals for Primary Prevention of Cardiovascular Disease
    • Diabetes Management - Pearls of Lipid Control
      Initiating and Monitoring Statin Therapy

      Webcasts/CME archive

       Recent cases - Cholesterol/Lipid Disorders
        There May be a Link Between Intrahepatic Cholestasis of Pregnancy and Familial Combined Hyperlipidaemia: A Case Report
        Marked Aortic Valve Stenosis Progression After Receiving Long-Term Aggressive Cholesterol-Lowering Therapy Using Low-Density Lipoprotein Apheresis in a Patient With Familial Hypercholesterolemia
        Acute Myocardial Infarction in an 18 Year Old South Indian Girl with Familial Hypercholesterolemia: A Case Report
        Eruptive Xanthomas and Acute Pancreatitis in a Patient with Hypertriglyceridemia
        Abetalipoproteinemia: Two Case Reports and a Literature Review

        Cases archive
          




        my personal edition > cholesterol/lipid disorders > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Ezetimibe and Other Statins Achieve Established Low-Density Lipoprotein Targets in Coronary Artery Disease: Presented at CCC

          By Marvin Ross

          TORONTO -- October 29, 2008 -- Statin use and, in particular, the use of ezetimibe is vital in reaching a low-density lipoprotein (LDL) goal of 2 mmol/L or less in the majority of patients with coronary artery disease, researchers stated here at the Canadian Cardiovascular Congress (CCC).

          Although statin use is a vital factor in reaching targets, combination therapy and especially the use of ezetimibe appears to be required in a sizable proportion of patients, noted Janek Senaratne, MD, Grey Nuns Hospital and University of Alberta, Edmonton, Alberta, speaking here on October 26.

          Dr. Senaratne and his fellow investigators studied 360 consecutive patients with coronary artery disease (CAD) who were enrolled in a cardiac rehabilitation program. The subjects' mean age was 61.8 years and over 75% were male (78.1%). Other characteristics of the sample were as follows: diabetes 21.1%; hypertension 51.7%; smokers 31.9%; and mean body mass index of 29.6.

          Subjects were taking atorvastatin (76.1%, mean dose 36.9 mg); simvastatin (12.2%, mean dose 32.0 mg); rosuvastatin (7.8%, mean dose 13.2 mg); pravastatin (1.1%, mean dose 35.0 mg); and gemfibrozil (0.6%, mean dose 1,200 mg). Only 2.2% were taking no medication.

          Combination therapy was required in 101 patients (28.1%). The agents used were ezetimibe (22.2%), fibrates (4.4%), and niacin (1.4%).

          Of the 360 patients, 307 (85.3%) were able to achieve an LDL of 2 mmol/L or less.

          Baseline total cholesterol, LDL, high-density lipoprotein, and triglycerides were 5.73 +- 0.06; 3.71 +- 0.06; 1.11 +- 0.01; and 2.22 +- 0.09, respectively. At the end of the rehabilitation program, the measures were 3.25 +- 0.03; 1.65 +- 0.02; 0.99 +- 0.01; and 1.36 +- 0.04, respectively.

          A univariate regression analysis found the following to be significant in achieving these levels: statin use, attending nutrition classes, and employment status (all with P < .001), as well as baseline cholesterol (P = .006); baseline LDL (P = .02); and time in rehabilitation (P = .04).

          In a multivariate regression analysis, variables having significant independent influence were statin use (P < .001), employment status (P < .001), and attending nutrition classes (P = .009).


          [Presentation title: Can the Currently Available Lipid Lowering Agents Achieve the LDL Targets They Have Established in Coronary Artery Disease. Abstract 056-002]




        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send